Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium

Area of Science:

• Ophthalmology
• Genetics
• Clinical Trials

Background:

• Inherited retinal diseases (IRDs) are a leading cause of blindness.
• Advances in precision medicine are driving the development of novel IRD treatments.
• Clinical trials for IRDs have significantly increased, necessitating specialized approaches.

Purpose of the Study:

• To review current accomplishments in IRD clinical trials.
• To identify existing challenges in the design, conduct, and analysis of these trials.
• To propose recommendations for accelerating the development and approval of effective IRD therapies.

Main Methods:

• Review of recent advancements and challenges in IRD clinical trials.
• Analysis of novel outcome measures and endpoints in small patient populations.
• Discussion of ethical considerations in IRD research.

Main Results:

• Significant progress has been made in IRD treatment development.
• Challenges remain in study design, ethical considerations, and participant identification.
• Recommendations are proposed to enhance trial efficiency and patient safety.

Conclusions:

• Accelerating the approval of effective IRD treatments requires collaborative efforts.
• Addressing trial design and ethical challenges is crucial for future progress.
• Continued discussion among stakeholders will drive innovation in IRD clinical research.